Get the Stockscreener App
3.9614
2.62%
0.1114
Sagimet Biosciences Inc Stock (SGMT) Latest News
Sagimet Biosciences Inc. (NASDAQ:SGMT) Receives $23.00 Consensus Price Target from Analysts - Defense World
Sagimet Biosciences (SGMT) Expected to Announce Earnings on Monday - Defense World
HC Wainwright Issues Positive Estimate for SGMT Earnings - Defense World
Sagimet Biosciences: Promising Future with Phase 3 MASH Trials and Strong Financial Position - TipRanks
HC Wainwright Reiterates Buy Rating for Sagimet Biosciences (NASDAQ:SGMT) - Defense World
Sagimet Biosciences Faces AI Integration Challenges: Security, Compliance, and Cost Risks Loom - TipRanks
Sagimet Biosciences Advances MASH Treatment with New Trials - TipRanks
Sagimet Biosciences Reports Full Year 2024 Financial Results and Provides Corporate Updates - GlobeNewswire
Sagimet’s FASN inhibitor cleared to enter clinic for acne - BioWorld Online
Sagimet Biosciences Inc. (SGMT) reports earnings - Quartz
Sagimet Biosciences Inc. SEC 10-K Report - TradingView
Sagimet's FDA Breakthrough Drug Enters Phase 3 Trials with $158M War Chest - StockTitan
Promising Developments in Sagimet Biosciences: IND Clearance for TVB-3567 and Ongoing Success of Denifanstat - TipRanks
Promising Pipeline and Positive Trial Data Support Buy Rating for Sagimet Biosciences - TipRanks
Sagimet Biosciences’ Strategic Expansion into Acne Treatment with Promising FASN Inhibitor TVB-3567 - TipRanks
Sagimet Reports Acne Drug Candidate Cleared for Clinical Trials -March 11, 2025 at 10:46 am EDT - Marketscreener.com
Sagimet Biosciences receives FDA nod to begin testing its therapy for acne -March 11, 2025 at 09:38 am EDT - Marketscreener.com
Sagimet Biosciences Announces Clearance of IND for FASN Inhibitor TVB-3567, to be Developed for the Treatment of Acne - SEC.gov
Sagimet Biosciences announces clearance of IND for FASN inhibitor TVB-3567 - TipRanks
Sagimet Biosciences Announces Clearance of IND for FASN - GlobeNewswire
Sagimet Biosciences Announces Clearance of IND for FASN Inhibitor TVB-3567, to be Developed for ... - The Bakersfield Californian
FDA Clears Groundbreaking Acne Drug: Sagimet's New FASN Inhibitor Targets 50M Patient Market - StockTitan
Sagimet Biosciences’ Denifanstat Should Be Worth More Today (NASDAQ:SGMT) - Seeking Alpha
Is Sagimet Biosciences Inc. (SGMT) the Best Get Rich Quick Stock to Invest In? - Insider Monkey
10 Best Get Rich Quick Stocks To Invest In - Insider Monkey
Brokerages Set Sagimet Biosciences Inc. (NASDAQ:SGMT) PT at $23.00 - Defense World
10 Hot Penny Stocks to Buy Now - Insider Monkey
Unveiling Hidden Gems: The Hot Penny Stock You Might Be Missing - Reporteros del Sur -
Sagimet Biosciences Inc. (SGMT): Among the Hot Penny Stocks to Buy Now - Insider Monkey
Sagimet Biosciences Inc. (NASDAQ:SGMT) Receives Consensus Rating of "Moderate Buy" from Analysts - MarketBeat
Sagimet Biosciences Announces Oral Presentation at the MASH - GlobeNewswire
Sagimet Biosciences Announces Oral Presentation at the MASH Pathogenesis and Therapeutic ... - The Bakersfield Californian
Could This New MASH Drug Transform Liver Disease Treatment? Key Phase 2b Results Revealed - StockTitan
FY2024 Earnings Estimate for SGMT Issued By Leerink Partnrs - MarketBeat
Technical analysis of Sagimet Biosciences Inc (SGMT) stock chart patterns - US Post News
FY2024 Earnings Forecast for SGMT Issued By Leerink Partnrs - Defense World
Keeping an Eye on Sagimet Biosciences Inc (SGMT) After Insider Trading Activity - Knox Daily
Sagimet Biosciences Inc (NASDAQ:SGMT) Up 47.7% Since 52-Week Low; YTD Rose 1.56% – Here’s What You Need To Do – Marketing Sentinel - Marketing Sentinel
Equities Analysts Issue Forecasts for SGMT FY2029 Earnings - MarketBeat
Prepare Yourself for Liftoff: Sagimet Biosciences Inc (SGMT) - SETE News
Sagimet Biosciences Inc (SGMT)’s results reveal risk - US Post News
Analytical Overview: Sagimet Biosciences Inc (SGMT)’s Ratios Tell a Financial Story - The Dwinnex
US Penny Stocks Spotlight: Gevo And 2 Other Promising Picks - Yahoo Finance
Buy Recommendation for Sagimet Biosciences: Denifanstat’s Unique Profile and Undervaluation Offer Compelling Investment Opportunity - TipRanks
What's Going On With Sagimet Biosciences Stock On Thursday? - MSN
JPMorgan Chase & Co. Boosts Stake in Sagimet Biosciences Inc. (NASDAQ:SGMT) - Defense World
Sagimet Biosciences Inc. (NASDAQ:SGMT) Given Average Recommendation of "Moderate Buy" by Brokerages - MarketBeat
This Vital Farms Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday - Benzinga
Sagimet Biosciences Inc. (NASDAQ:SGMT) Given Consensus Rating of "Moderate Buy" by Analysts - MarketBeat
0.37%
0.88%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):